A new clinical validation study published in European Urology highlights the potential of a whole-genome sequencing approach to revolutionize minimal residual disease (#MRD) detection in patients with muscle invasive bladder cancer. Developed by C2i Genomics, which was recently acquired by Veracyte, this innovative MRD method can help pave the way for more personalized and effective care for patients. Learn more about how this technology can transform MRD assessment and improve patient outcomes. https://lnkd.in/g994q5C9
Veracyte, Inc.’s Post
More Relevant Posts
-
New research published in JAMA Network Open highlights the promise of combining genomic analyses with clinical outcome data to support prostate cancer treatment. Utilizing Veracyte's Decipher Prostate Genomic Classifier, this study reviewed over 92,000 patients, showcasing the potential for more personalized and timely treatment strategies. https://lnkd.in/euZERMRh #ProstateCancer #PersonalizedCare
Longitudinal Prostate Cancer Transcriptomic and Clinical Data Linkage
jamanetwork.com
-
We are pleased to announce that Veracyte’s Afirma Genomic Sequencing Classifier (GSC) now has expanded Medicare coverage for patients with “Bethesda V” thyroid nodules, or those that are suspicious for cancer. This pivotal milestone allows thousands of patients access to advanced technology to help guide their treatment based on the molecular characteristics of their nodules. John Leite, our Chief Commercial Officer, CLIA Business, shares his perspective on this important development for patients and personalized medicine. #Endocrinology #ThyroidCancer
Veracyte’s Afirma GSC test will now be covered by Medicare for patients with #ThyroidNodules that are suspicious for #ThyroidCancer. Here’s an article I wrote about why this is good news for patients and for personalized medicine more generally.
New Medicare Coverage for the Afirma Genomic Sequencing Classifier: A Step Forward in Personalized Thyroid Cancer Care
John Leite on LinkedIn
-
New data published in ESMO Open show that Veracyte’s Prosigna Breast Cancer Assay significantly influenced treatment decisions for nearly one-third of physicians treating patients with early-stage breast cancer. Learn more about the study and how Prosigna can help guide more confident treatment decisions in this article authored by Jenna Lefkowits, our Executive Director for IVD Marketing & Strategy.
Veracyte’s Prosigna Breast Cancer Assay is revolutionizing breast cancer care globally. We’re thrilled to see new data in ESMO Open showing how Prosigna influenced treatment recommendations for nearly one-third of patients, including reducing the recommendation of chemotherapy and its potential toxic side effects. I share more of my thoughts and highlights from the latest readout from the EMIT1 study here. #BreastCancer #Prosigna #EMIT1 #subtypes #LuminalB #LuminalA #intrinsicmolecularsubtypes
Revolutionizing Breast Cancer Treatment: New Data on Prosigna Test Published in ESMO Open
Jenna Lefkowits on LinkedIn
-
New findings derived from Veracyte’s Afirma GRID (Genomic Resource for Intelligent Discovery) tool suggest the potential of novel molecular signatures to identify patients with thyroid nodules or cancer who have aggressive disease. The findings, which could potentially help clinicians further individualize care based on each patient’s tumor biology, were presented today at ENDO 2024. #ENDO2024 #Endocrinology #ThyroidCancer https://lnkd.in/ewGuqB6C
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid Tumors | Veracyte, Inc.
investor.veracyte.com
-
Join us at ASCO 2024 to explore Veracyte’s innovative approach to minimal residual disease (MRD) detection. Our team is at booth 35131 and ready to discuss how our advanced whole-genome sequencing and AI capabilities are transforming cancer care in collaboration with our biopharma partners. #ASCO24 #AIinHealthcare #MRD
-
-
This morning at ASCO 2024: From 9 a.m. – 12 p.m. CDT, don’t miss several poster sessions that demonstrate the capabilities of Veracyte’s Prosigna Breast Cancer Assay and Decipher Bladder Genomic Classifier. Our team looks forward to discussing these presentations with the oncology community - stop by booth 35131 to connect with our experts! #ASCO24 #BreastCancer #BladderCancer
-
Day 1 at ENDO 2024! Stop by booth 709 to learn more about how our Afirma® Genomic Sequencing Classifier can help you personalize diagnosis and treatment for your patients with thyroid nodules, or book a meeting with Dr. Joshua Klopper, Veracyte’s Medical Director for Endocrinology. We’ll be here through Tuesday and look forward to connecting with you in Boston. https://lnkd.in/eKWxzuE6 #ThyroidCancer #Endocrinology #ENDO2024
ENDO 2024 – Request a Meeting with Dr. Joshua Klopper, Medical Director of Endocrinology at Veracyte
cloud.mail.veracyte.com
-
Hello from the 2024 ASCO Annual Meeting! The Veracyte team is thrilled to be in Chicago and looks forward to connecting with others at the meeting – join us at booth 35131 to learn more about how we're transforming cancer care worldwide. #ASCO24
-
-
On #WorldThyroidDay, we celebrate the strides made in personalizing diagnosis and treatment for thyroid nodules. For years, indeterminate thyroid nodules posed a significant challenge, often leading to unnecessary surgeries. At Veracyte, we are committed to driving innovation in this space, empowering clinicians with comprehensive insights to make more accurate treatment decisions, and helping patients navigate thyroid nodule diagnosis. #ThyroidCancer #endocrinology
bioinformagician
1moNice work, Boris Oklander and team!